Gramex

Quick links to important sections

Gramex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gramex

Property Description
Active ingredient Metronidazole
Forms Tablet, Capsule, Suspension, Injectable Solution, Topical Cream/Gel
Pharmacological class Nitroimidazole Antimicrobial (Antibiotic & Antiprotozoal Agent)
General purpose Combating infections caused by anaerobic bacteria and protozoa
Origin Synthetic (C-nitro compound, prodrug)

Defining Gramex: What Type of Medicine is Metronidazole?

Gramex is a pharmaceutical preparation whose primary active ingredient is Metronidazole, classifying it formally as a Nitroimidazole Antimicrobial agent. This pharmacological class is defined by the ability to combat two major categories of pathogens: certain anaerobic bacteria and single-celled organisms known as protozoa. It is recognized for its broad utility against these target microbes. Unlike traditional antibiotics, this synthetic agent is both an antibiotic and an antiprotozoal agent, which defines the core identity and wide therapeutic applications of the drug.

Composition and Origin: Is Metronidazole a Single-Ingredient Synthetic Drug?

The medicine is composed primarily of Metronidazole (C6H9N3O3), an organically derived synthetic chemical substance that functions as a prodrug and is supplied as a single-ingredient product. A prodrug is designed to be chemically inactive upon administration, requiring transformation within the targeted microbial cells to become fully active. Metronidazole exhibits selective action against obligate anaerobes, possessing targeted efficacy against bacteria that cannot survive in oxygenated environments. This specialized composition ensures the drug is activated only within the susceptible bacteria and protozoa, where it exerts its effect by disrupting the microbial cells' DNA and essential nucleic acids.

Gramex Forms and General Therapeutic Purpose

Metronidazole is available in several versatile pharmaceutical preparations to facilitate various administration needs, including oral tablets, capsules, and oral suspension for systemic treatment, as well as an injectable solution and topical cream or gel. The overarching therapeutic purpose of the medicine is to achieve a bactericidal (cell-killing) effect that eliminates the microbial source of an infection, specifically targeting susceptible anaerobic bacteria and protozoa. The availability of oral, intravenous, and topical forms ensures that the medicine can be delivered effectively to treat both generalized and localized infections.

What side effects are possible with Gramex?

Possible side effects and safety information

The safety profile of Gramex (Metronidazole) is formally established by regulatory authorities and classified by the physiological system affected and the frequency of occurrence.

Frequency-Classified Adverse Reactions

The most frequently documented adverse reactions are categorized as Common and typically involve the gastrointestinal and nervous systems, including nausea, headache, diarrhea, abdominal pain, and the sensory disturbance of a metallic taste. Rare events are explicitly documented, such as serious neurological reactions and severe hepatotoxicity.

System-Organ Class Common Adverse Reactions
Gastrointestinal Disorders Nausea, Vomiting, Diarrhea, Metallic Taste
Nervous System Disorders Headache, Dizziness
Blood and Lymphatic Reversible Leukopenia (Uncommon)

Serious Safety Considerations

The official labeling notes a risk for Serious Adverse Reactions, which require prompt observation. These include encephalopathy and convulsive seizures, classified as rare CNS toxicities. Furthermore, peripheral neuropathy is a serious, potentially persistent effect documented, particularly in association with prolonged treatment or high doses. Rare, severe hepatotoxicity and acute liver failure have also been officially reported.

Population-Specific Safety Notes

The medicine's regulatory profile includes specific notes for certain patient groups. Individuals with severe hepatic impairment may experience significantly increased systemic exposure, increasing the risk of adverse reactions. The medicine is explicitly contraindicated in patients with Cockayne syndrome due to reports of severe, potentially fatal liver complications.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Gramex (Metronidazole) overdose describes specific manifestations and mandatory management protocols. Acute overdose, which has been reported with single oral doses, may present with gastrointestinal distress, including nausea and vomiting, alongside neurological signs such as ataxia (loss of coordination).


Documented Severe Outcomes

A primary concern in cases of high cumulative exposure or acute overdose is neurotoxicity. Severe outcomes documented in official labeling include convulsive seizures, encephalopathy (abnormal brain function), and peripheral neuropathy. Regulatory authorities explicitly state that in the event of suspected overdose or the presentation of these severe neurological symptoms, immediate medical attention must be sought, and emergency services should be contacted.


Management and Special Considerations

No specific antidote is known for Metronidazole overdose. Consequently, the mandated approach to management is symptomatic and supportive therapy. The procedure of Hemodialysis is documented as effective for removing the drug and its metabolites from the system. Furthermore, specific populations require heightened awareness: patients with End-Stage Renal Disease (ESRD) need monitoring for metabolite accumulation, and patients with Cockayne Syndrome face a serious risk of acute hepatic failure. This regulatory profile strictly defines the symptoms that necessitate immediate medical action and outlines the required procedural steps for healthcare providers.

Therapeutic Uses of Gramex

What Gramex Treats: Main Uses and Benefits

Gramex (Metronidazole) is commonly used in clinical settings that involve acute or unstable symptom patterns caused by specific anaerobic bacteria and certain protozoa. The medication is applied across domains where additional symptomatic support is needed to ease the overall symptom burden. It is used for a variety of conditions presenting with systemic or localized discomfort.

It is relevant for managing serious conditions like sepsis, brain abscesses, and acute intra-abdominal infections, in addition to specific parasitic diseases such as amebiasis and trichomoniasis. The drug is also commonly used to manage localized symptoms of infection, including those associated with bacterial vaginosis, dental abscesses, and the inflammatory lesions of rosacea.

“The therapy is used in areas where short-term symptom management is appropriate to ease distress and contributes to easing the overall symptom load.”

The use of this medication may help manage symptoms related to systemic imbalance, such as high fever and general malaise, and is commonly applied in scenarios where additional management of acute pain and swelling is required, offering supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Anaerobic and Protozoal Symptoms Gramex provides supportive relief across multiple domains, assisting with managing symptoms that create noticeable physiological strain, such as severe diarrhea, persistent abnormal discharge, and acute localized pain and inflammation.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Gramex (Metronidazole)

The eligibility for using Gramex (Metronidazole) is defined by official regulatory documents, specifying populations with absolute prohibitions and those requiring conditional use.

Contraindicated Populations Official Regulatory Status
Prior hypersensitivity to Metronidazole or other nitroimidazole derivatives Absolute Prohibition
Patients with Cockayne Syndrome Absolute Prohibition due to risk of fatal hepatotoxicity
Patients who have taken disulfiram within the last two weeks Absolute Prohibition due to risk of psychotic reactions
Treatment of trichomoniasis during the first trimester of pregnancy Absolute Prohibition for this specific indication
Condition-Specific Eligibility Rules Official Regulatory Status
Severe Hepatic Impairment (Child-Pugh C) Conditional use; monitoring and dose reduction are necessary
End-Stage Renal Disease (ESRD) Conditional use; monitoring for metabolite accumulation is recommended
Active or Chronic CNS Disease Use requires caution
Breastfeeding women Not recommended; interruption of breastfeeding is often required
Pediatric Use Established for some indications (e.g., amebiasis), but use is not established for all oral forms
Older Adults Use is generally permitted, though caution is advised due to age-related decline in organ function

The official eligibility profile clearly defines patient groups who must not use the medicine, primarily based on allergy, rare genetic disorders, or drug-drug interactions. Other patient groups, such as those with severe liver disease or kidney impairment, require special regulatory consideration and monitoring to permit conditional use.

What should I know about interactions with other medicines?

Interactions with other medicines and products — Official Regulatory Information for Gramex (Metronidazole)

Category Official Regulatory Statement
Medicinal product categories with documented interactions Oral Anticoagulants, Antiepileptics, Immunosuppressants, Chemotherapeutics, Cimetidine, Alcohol.
Specific interacting medicines (if explicitly listed) Warfarin, Disulfiram, Phenytoin, Phenobarbital, Busulfan, Lithium, Ciclosporin, Tacrolimus, 5-Fluorouracil.
Mechanistic basis of interactions (only if stated in label) Inhibition of metabolism, resulting in reduced drug clearance and increased plasma concentrations; Accelerated metabolism of metronidazole by certain CYP inducers.
Timing-based interaction rules (if applicable) The medication is formally contraindicated in patients who have taken Disulfiram within the last two weeks.
Population-specific interaction notes (if applicable) Patients with Severe Hepatic Impairment exhibit slowed metabolism, leading to metronidazole plasma accumulation. Monitoring is recommended for patients with End-stage Renal Disease (ESRD) due to the potential accumulation of metabolites.
Interaction-related restrictions Consumption of Alcohol or products containing propylene glycol is prohibited during therapy and for at least three days after discontinuation.

Interaction Classifications (High-Level)

The profile includes Formal Contraindications (Alcohol, Disulfiram) and Clinically Significant Interactions documented across official regulatory labels (FDA, EMA, MHRA).

Resulting Interaction Structure

Official interaction statements confirm that co-administration with oral anticoagulants like Warfarin potentiates their effect by inhibiting their metabolism, potentially prolonging prothrombin time. Co-use with Phenytoin decreases metronidazole clearance, while Phenobarbital accelerates metronidazole's own metabolism. Furthermore, Metronidazole increases the plasma concentrations of drugs such as Lithium, Busulfan, and Tacrolimus, elevating the risk of exposure-related effects. The interaction with alcohol is prohibited due to the risk of a severe disulfiram-like reaction.

Mechanism of Action

Targeted Exploitation of Anaerobic Metabolism

Metronidazole, the active molecule in Gramex, functions as a chemically inactive prodrug that undergoes selective activation within the target pathogen. This process is driven by the unique low redox potential environment and electron transport proteins (such as ferredoxin) found exclusively within susceptible anaerobic bacteria and protozoa. This selective mechanism ensures the drug's activity is highly localized, preventing activation in non-target cells.

DNA Damage and Irreversible Cytotoxicity

Upon accepting low-potential electrons, the prodrug is rapidly converted into highly reactive radical intermediates (nitro radical anions) and subsequent cytotoxic metabolites. These active species damage the microbial DNA, causing strand breakage and destabilization of the helix. This action leads to the irreversible inhibition of nucleic acid synthesis, which produces a bactericidal and antiprotozoal effect that results in a reduction of viable microbial cells.

Mechanism Constraint by Oxygen Interference

The entire cytotoxic cascade is constrained by the presence of oxygen, which competes for the activating electron and rapidly reoxidizes the reactive intermediate back to the inactive parent compound. This chemical competition is the factor that constrains the mechanism's effectiveness against aerobic organisms.

Dosage and Administration Information

How Gramex (Metronidazole) is Used

Gramex is used according to established protocols that define its administration route, dosage, and duration, based on the specific infection being treated. The medicine is available for oral intake (as tablets, capsules, or suspension), by intravenous (IV) infusion for serious systemic infections, and through topical application for localized conditions.


Dosing and Administration Schedule

Dosing is non-uniform and highly dependent on the medical indication. For severe anaerobic infections, treatment often begins with a high IV dose followed by maintenance doses administered every six to eight hours. The total daily dosage must not exceed 4 grams. For certain parasitic diseases, like trichomoniasis, regimens include a single oral dose or a seven-day course of lower doses.


Procedural Use Requirements

Procedural Requirement Instruction Principle
Oral Intake Recommended to be taken with or immediately after food to improve gastrointestinal tolerability.
IV Administration Requires infusion over a defined period, typically 30 to 60 minutes, and is primarily used in an inpatient setting.
Hepatic Adjustment A 50% dose reduction is mandatory for patients with diagnosed severe hepatic impairment (liver function difficulties) to prevent accumulation of the drug.
Special Forms Extended-release tablets must be swallowed whole and cannot be crushed, broken, or chewed.
Duration Therapy is administered in defined short-term courses, commonly ranging from 5 to 14 days, depending on the site and type of infection.

These standardized guidelines ensure that the medicine is delivered using the appropriate method and schedule for its intended systemic or localized purpose.

Recent Clinical Evidence

Research evidence / Overview of studies for Gramex (Metronidazole)

Evidence for Infections Caused by Anaerobic Bacteria

The research base for use against anaerobic bacteria relies on older established clinical trials and regulatory reviews. These studies research examined systemic infections, such as sepsis, and localized issues, including intra-abdominal or gynecological infections. Researchers tracked Clinical Cure/Success and post-operative infection rates in observed populations. Studies observed patterns related to these measurements across various infections; however, the evidence base relies significantly on older clinical data. A gap exists in recent, large-scale Randomized Controlled Trials (RCTs) comparing Metronidazole to many newer antibiotics across all specific infection subsets.

Evidence for Infections Caused by Protozoa

Research was evaluated in clinical trials for parasitic diseases like amebiasis (adult and pediatric patients) and trichomoniasis. For amebiasis, studies tracked Parasitological Cure (elimination of the parasite), noting that clearance from the intestinal lumen was noted as inconsistent across studies. For trichomoniasis, RCTs compared single-dose versus multi-day regimens. Data show patterns related to varying eradication rates depending on the duration, and the frequency of Recurrence remains a documented observation.

Evidence for Other Specific Infections and Limitations

Clinical trials research examined specific localized conditions, including bacterial vaginosis (BV) and rosacea (topical formulations). For BV, studies reported high short-term measurements of cure, but long-term follow-up consistently described a Documented frequency of Recurrence. For Rosacea, trials measured changes in Inflammatory Lesions over a period of 8 to 12 weeks.

In Clostridioides difficile Infection (CDI) studies, comparative trials findings were mixed when assessing Clinical Success, particularly in patients with severe disease. Research data for certain groups remain insufficient, as the follow-up durations were limited for many conditions. Evidence related to amebiasis was evaluated in both adult and pediatric patients, but other research, such as that for rosacea, is mainly limited to adults.

Frequently Asked Questions (FAQ)

Common questions about Gramex (FAQ)


Q: Does Gramex cure the condition, or does it only help manage the symptoms?

A: Gramex contains metronidazole, which is classified as both a bactericidal and an antiprotozoal agent. This means its mechanism of action is designed to kill the susceptible anaerobic bacteria and protozoa that cause the infection. This cell-killing mechanism is the basis for its therapeutic action against susceptible pathogens.


Q: Can Gramex cause long-term changes to my body or overall health?

A: Official safety information notes a risk of serious neurological reactions, including peripheral neuropathy (nerve damage). This effect is reported to be potentially persistent in some patients, especially those who received prolonged treatment or high doses.


Q: Can Gramex be used safely with common over-the-counter pain relievers?

A: Regulatory documents primarily list clinically significant interactions with certain prescription medications. Information on every common over-the-counter pain reliever is not specifically detailed across all official labels. Therefore, it is important for patients to inform their prescribing healthcare provider about all medications they are currently taking.


Q: Does Gramex interact with any vitamins or herbal supplements?

A: Official drug interaction information focuses on medicines and does not typically provide exhaustive data on every vitamin or herbal supplement. To ensure full awareness of any potential risks, it is important for patients to disclose the use of all supplements to their healthcare provider.


Q: Is Gramex suitable for use by individuals with pre-existing mild kidney problems?

A: Regulatory guidance on Gramex use in patients with kidney function difficulties indicates that a dose adjustment is typically not required for those with mild-to-moderate renal impairment. This suggests the medicine's clearance is not significantly affected in these specific cases.


Q: Does Gramex require regular monitoring through blood tests?

A: Official product information recommends monitoring blood counts, specifically total and differential leukocyte counts. This is generally noted for patients receiving repeated courses of treatment or those with a history of blood disorders.


Q: Can Gramex affect my ability to drive or operate machinery?

A: Official patient information leaflets state that Gramex may cause dizziness as a common side effect. Because of this, patients are advised not to drive or operate heavy machinery until they understand how the medicine affects their individual alertness.


Q: Is Gramex a controlled substance or narcotic?

A: The medicine’s active ingredient, metronidazole, is officially classified as a nitroimidazole antimicrobial agent. It is not listed or scheduled as a narcotic or controlled substance under the federal Controlled Substances Act.


Q: What is the mechanism of action of Gramex, in simple terms?

A: Gramex works through a selective process where the drug is activated only inside susceptible anaerobic bacteria and protozoa. Once activated, it creates a substance that damages the microbe’s DNA. This action inhibits the microbe’s ability to create necessary cell material, ultimately leading to the death of the cell.


Q: What are the common signs of a severe allergic reaction to Gramex?

A: Official warnings describe the signs of a severe allergic reaction, or hypersensitivity, which include skin rash, hives, and itching. More severe signs include swelling of the face, lips, tongue, or throat, alongside severe dizziness or difficulty breathing.


Q: Did the clinical trials for Gramex include a diverse range of patient populations?

A: Studies and official documentation indicate that the medicine's effects have been specifically examined in certain patient populations. These include older adults and individuals with impaired organ function, such as those with hepatic or renal difficulties.


Q: Is the effectiveness of Gramex consistent across all patient groups studied?

A: Official studies show that the way the body processes and clears the drug (pharmacokinetics) can differ across certain patient groups. For example, older adults and those with liver or kidney difficulties may show different rates of drug clearance, which may affect overall exposure.


Q: Does the efficacy of Gramex change if it is taken with food or on an empty stomach?

A: While taking the oral medication with or immediately after food is primarily advised to improve gastrointestinal comfort, official studies also indicate that food may influence the absorption of certain dosage forms.


Q: Why is Gramex not approved for use in younger children or adolescents?

A: The regulatory status indicates that the use of metronidazole is not yet fully established for all specific infections or all dosage forms in children and adolescents. This limitation is due to the lack of sufficient safety and effectiveness data in these specific patient groups.


Q: What are the safety concerns related to using Gramex during pregnancy or breastfeeding?

A: For the treatment of trichomoniasis, the medicine is formally contraindicated during the first trimester of pregnancy. Regarding breastfeeding, official information indicates that the drug passes into breast milk, and a decision must be made to either interrupt nursing or discontinue the medication.


Q: Can Gramex be used by someone who has mild liver impairment?

A: Studies have examined the use of the medicine in patients with mild liver impairment. They show that while use is possible, there is an increase in the systemic exposure of the drug in this specific population compared to those with healthy liver function.


Q: Why do official sources recommend caution when starting Gramex?

A: Official regulatory sources advise caution due to the potential for several serious risks. These include the risk of severe neurological toxicity, the potential for clinically significant drug interactions, and the possibility of increased drug exposure in patients with impaired kidney or liver function.


Q: Is Gramex known by any other brand name?

A: The active ingredient, metronidazole, is available under multiple brand names globally. These may include commonly known names such as Flagyl or Metrogel, depending on the country and specific dosage form.


Q: What happens if I stop taking Gramex suddenly?

A: As an antimicrobial agent, stopping the medication too soon may increase the risk of the original infection recurring. Additionally, discontinuing the medicine prematurely may contribute to the development of drug-resistant bacteria.


Q: What should I expect if Gramex does not seem to be working after the initial period?

A: If symptoms of infection do not improve or worsen, healthcare providers may need to be contacted to evaluate for potential reasons, such as drug resistance or an alternative diagnosis.


Q: Is Gramex available as a generic medication?

A: Yes, the active ingredient metronidazole is widely available in generic form. However, not every specific dosage form, such as specialized sustained-release tablets or topical gels, may have an approved generic product available.


Q: Does Gramex have any known interactions with birth control medication?

A: Official guidelines indicate that metronidazole is not known to reduce the effectiveness of combined hormonal contraceptives. However, as interactions can be complex, it is important for patients to inform their healthcare provider about their use of birth control and all other medications.


Q: What are the ingredients in Gramex besides the active one?

A: Gramex contains the active ingredient metronidazole and several inactive ingredients (excipients). These can include compounds like cellulose, titanium dioxide, or certain dyes, and the exact list varies depending on the specific dosage form (e.g., tablet or capsule).


Q: What does the patient information leaflet say about missing a dose of Gramex?

A: The standard instruction in the official patient information leaflet is to take the missed dose as soon as the patient remembers it. The standard instruction is that the patient should only take the next scheduled dose, and a double dose should not be taken to compensate for a missed dose.


Q: Does Gramex have the potential to interact with other prescription medications not listed in the official documents?

A: Official documents detail all clinically significant drug interactions that have been established by regulators. However, it is important that patients inform their healthcare provider of all medications they use to check for potential unlisted interactions.


Q: How quickly is Gramex cleared from the body after the last dose?

A: Pharmacokinetic studies of the active ingredient, metronidazole, in healthy subjects indicate that its average elimination half-life is approximately eight hours. The half-life is the time it takes for the concentration of the drug in the body to reduce by half.


Q: What kind of research is currently being done on Gramex?

A: Active research is ongoing, and official government registries document various studies related to metronidazole. These studies include the comparison of different dosage forms, such as delayed-release capsules versus immediate-release tablets, to evaluate their safety and how the body handles the medicine.

How should Gramex be stored and disposed of?

How to Store and Dispose of Gramex?

Specific official storage and handling requirements for Gramex (such as exact temperature, light protection, or in-use stability) are not detailed in accessible regulatory documents. It should be stored and protected from children according to the manufacturer's labeled instructions.

For disposal of unused or expired medication, general governmental guidelines apply. The preferred method is to use authorized drug take-back programs at pharmacies or community events.

If a take-back option is not available, check if the drug is on a specific list for flushing due to high risk of harm from accidental ingestion. If not on the flush list, dispose of it in the household trash after mixing the medicine with an unappealing substance (like used coffee grounds or dirt) and placing the mixture in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gramex found in:

A-Z Index: